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Individuals carrying melanocortin 1 receptor gene
variants have an increased risk for the development
of cutaneous melanoma. Melanocortin 1 receptor
gene variants are also associated with other risk
factors for melanoma such as fair skin and red hair.
We evaluated the relationship of melanocortin 1
receptor gene variants, fair skin, red hair and the
development of melanoma in 123 patients with cuta-
neous melanoma and 385 control subjects. To ana-
lyze the association between melanocortin 1 receptor
gene variants and skin type or hair color we also
made use of 453 patients with nonmelanoma skin
cancer. We analyzed the coding sequence of the
melanocortin 1 receptor gene region by single-
stranded conformation polymorphism analysis, fol-
lowed by DNA sequence analysis. Risk of melanoma
dependent on the various melanocortin 1 receptor
variant alleles was estimated by exposure odds ratios.
The analyses of all different melanocortin 1 receptor
gene variants combined, showed that the presence of
melanocortin 1 receptor gene variants amounted to a
higher melanoma risk, which, in strati®ed analyses,
was independent of skin type and hair color. The
odds ratios after adjusting for skin type were 3.6
(95% CI 1.7±7.2) for two variants and 2.7 (95% CI
1.5±5.1) for one variant, respectively. Compound
heterozygotes and homozygotes for the Val60Leu,
Val92Met, Arg142His, Arg151Cys, Arg160Trp,
Arg163Gln, and His260Pro variants had odds ratios
of about 4 to develop melanoma, whereas hetero-
zygotes for these variants had half the risk. The pres-
ence of the melanocortin 1 receptor gene variant
Asp84Glu appeared to impose the highest risk for
cutaneous melanoma with odds ratios of 16.1 (95%
CI 2.3±139.0) and 8.1 (95% CI 1.2±55.9) in com-
pound heterozygotes and heterozygotes, respectively.
The broad con®dence intervals, when the different
variants were analyzed separately, however, do not
allow drawing de®nite conclusions about the magni-
tude of these risks. Of the more frequently occurring
melanocortin 1 receptor variant alleles the Asp84Glu,
Arg142His, Arg151Cys, Arg160Trp, His260Pro, and
Asp294His variants were strongly associated with
both fair skin and red hair. The Val60Leu, Val92Met,
and Arg163Gln variant alleles, however, were only
weakly or not associated with fair skin type and/or
red hair, which further illustrates the ®nding that
skin type, hair color, and melanoma are independent
outcomes of the presence of melanocortin 1 receptor
gene variants. We conclude that numerous melano-
cortin 1 receptor variants predispose to cutaneous
melanoma and that possibly the Asp84Glu variant
confers the highest risk. This predisposition is largely
independent of skin type and hair color. Key words:
epidemiology/melanoma/melanocortin 1 receptor gene. J
Invest Dermatol 117:294±300, 2001
V
ariants of the melanocortin 1 receptor-gene (MC1R
gene) are associated with an increased risk for the
development of cutaneous melanoma (Valverde et al,
1996; Rees and Healy, 1997; Healy et al, 1999;
Palmer et al, 2000). MC1R gene variants are also
associated with phenotypical features such as fair skin and red
hair that carry a higher risk for both melanoma and
nonmelanoma skin cancer (Bliss et al, 1995; Valverde et al,
1995; Katsambas and Nicolaidou, 1996; Rees and Healy, 1997;
Flanagan et al, 2000; Harding et al, 2000; Healy et al, 2000;
Palmer et al, 2000; Bastiaens et al, 2001; Box et al, 2001).
Furthermore, the MC1R gene is closely associated with sun
sensitivity in the majority of individuals without red hair (Healy
et al, 2000). Considering these associations the MC1R gene,
therefore, is of substantial importance as a susceptibility gene for
sunburn, photoaging, and cutaneous melanoma (Healy et al,
2000).
The MC1 receptor located on chromosome 16q24.3 is a seven-
pass transmembrane, G-protein coupled receptor that has high
af®nity for a-melanocyte-stimulating hormone (a-MSH)
(Chhajlani and Wikberg, 1992; Mountjoy et al, 1992; Healy et al,
1998). Different variants of the MC1R gene can lead to a change in
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ligand binding, a change in function, or loss of function of the
MC1 receptor (Cone et al, 1996; Valverde et al, 1996; Box et al,
1997; Koppula et al, 1997).
The effect of the MC1 receptor on melanogenesis is mediated
through the activation of adenylyl cyclase to elevate cyclic
adenosine monophosphate levels after binding with a-MSH and
adrenocorticotropic hormone (Mountjoy et al, 1992). Generally,
stimulation with a-MSH leads to eumelanin synthesis which is
considered predominantly photoprotective, but variations in the
MC1R gene of which more than 20 have been reported may lead
to a different response (Rees and Healy, 1997; Healy et al, 1998).
Loss of function variants may lead to reduced cyclic adenosine
monophosphate production after stimulation with a-MSH result-
ing in increased levels of pheomelanin which is predominantly
found in individuals with fair skin and red hair and which may
contribute to an increased cancer risk by generating free radicals
following ultraviolet exposure (Burchill et al, 1986; Chhajlani and
Wikberg, 1992; Mountjoy et al, 1992; Barsh, 1996; Suzuki et al,
1996; FraÈndberg et al, 1998; Smith et al, 1998; SchioÈth et al, 1999).
Several studies have speci®cally tried to elucidate which MC1R
gene variants are of particular interest in the development of
cutaneous melanoma (Valverde et al, 1996; Ichii-Jones et al, 1998;
Palmer et al, 2000). A limitation of these studies, however, is that
only a limited number of particular MC1R gene variants was
studied in sometimes small numbers of patients and controls.
Valverde et al (1996) studied known MC1R variants in the
second (codons 64±106: e.g., Asp84Glu, Asn91Asp, Val92Met) and
seventh (codons 278±300: e.g., Asp294His) transmembrane
domains in 43 melanoma cases and 44 controls, and they reported
that MC1R variants were more common in melanoma cases than
controls. They found that the Asp84Glu accounted for most of this
difference as this variant was present in 10 of the melanoma cases
and not in the controls. In Valverde et al's (1996) study, the
contribution of MC1 receptor alleles seemed largely independent
of skin type.
A study by Ichii-Jones et al (1998) evaluated the Asp84Glu,
Val92Met, and Asp294His variants in a large but heterogeneous
population consisting of 306 cases with in situ melanoma, lentigo
melanoma, nodular melanoma, and super®cial spreading melanoma
in comparison with 190 controls. They were not able to detect a
difference between the melanoma cases and controls. However,
after correction for imbalances with age, gender, and skin type, the
association of the Asp84Glu variant with increased risk of
melanoma approached signi®cance (p = 0.069, odds ratio = 3.0,
95% CI 0.9±9.6).
Palmer et al (2000) studied six MC1R variants (Val60Leu,
Asp84Glu, Arg151Cys, Arg160Trp, Asp294His, and 537insC) in
460 cases selected from high-risk, intermediate-risk and low-risk
families with familial melanoma in comparison with 399 controls.
The MC1R gene variants Arg151Cys, Arg160Trp, and Asp294His
were more common in individuals with cutaneous malignant
melanoma. The odds of melanoma increased 2.2-fold (95% CI 1.6±
3.0) in individuals carrying one of these three variants, and it
increased 4.1-fold (95% CI 2.1±7.9) if at least two variants were
carried. Among pale-skinned individuals alone, this association
between MC1R variants and cutaneous melanoma was absent, but
it persisted among those reporting a medium or olive/dark
complexion. In Palmer et al's (2000) study no association could
be demonstrated between the Asp84Glu variant and cutaneous
melanoma.
The discrepancies in the different studies prompted us to
investigate the relationship between MC1R gene variants and
cutaneous melanoma in a cohort of Dutch patients. The question
remains open whether many of the numerous MC1R variants
predispose to cutaneous melanoma, or whether certain variants
confer higher risk than others (Healy et al, 1999). Speci®cally the
role of the Asp84Glu variant merits further study as this variant is
not as frequent as previously suspected in melanoma patients
(Valverde et al, 1996; Healy et al, 1999). The speci®c aims of this
study therefore were to assess whether: (i) the association between
MC1R gene variants and cutaneous melanoma also exists in a large
cohort of Dutch patients, and (ii) with which variants this
association is most prominent. We analyzed the coding region of
the MC1R gene region by single-stranded conformation poly-
morphism analysis, followed by DNA sequence analysis.
MATERIALS AND METHODS
Study population The Leiden Skin Cancer study was initiated in
1997 with the objective to assess the relative risks associated with known
and suspected risk factors for skin cancer in a Dutch cohort of patients
with melanoma and nonmelanoma skin cancer compared with control
persons (Bastiaens et al, 2001; De Hertog et al, 2001). Except for the
analyses to calculate the association between MC1R variants and skin
type or hair color, the study reported here was restricted to nonfamilial
cutaneous melanoma and controls. The Medical Ethics Committee
approved the study protocol and informed consent was obtained from all
participants in the study.
Control subjects, aged 30±80 y of age were recruited for this study at
the ophthalmology outpatient department at the Leiden University
Medical Center. Ophthalmology patients were chosen to represent the
controls because this group consisted of patients visiting the same
university hospital and were a good representation of patients living in
the same demographic area. Furthermore, eye conditions are usually not
related to factors that have been identi®ed as being a risk factor for skin
cancer in general. Controls were excluded when they had an intraocular
melanoma or any type of skin cancer in their medical history. Both cases
and controls were excluded from participation in this study when they
were transplant recipients or suffered conditions associated with an
increased risk for skin cancers such as xeroderma pigmentosum and
Gorlin's syndrome (basal cell nevus syndrome) or when they could be
classi®ed as being skin type V or VI according to Fitzpatrick's skin type
classi®cation, which is associated with a decreased risk for skin cancer
(Fitzpatrick, 1988).
Collection of data on risk factors for cutaneous melanoma The
visit at the dermatology outpatient clinic consisted of a standardized
personal interview by a trained interviewer. Participants were not
informed about our research objectives and interviewer or dermatologists
were not informed about the case or control status of the participating
subjects. Following the interview a total skin examination was performed
by a board-certi®ed dermatologist who was not informed about the
patient's case or control status.
The physical examination was performed according to a set protocol
and data were entered on to a preprinted examination sheet. The
dermatologist was requested to collect information on eye and hair color,
the amount of freckles and lentigines, number and localization of normal
and clinically atypical nevi and the presence of clinically manifest skin
cancer. Skin types were assessed as always burn, never tan (skin type I);
always burn, then tan (skin type II); always tan, sometimes burn (skin
type III); and always tan, never burn (skin type IV) (Fitzpatrick TB,
1988). Hair color was retrospectively assessed as hair color at age 20 and
was classi®ed as black, brown, dark blond, light blond or red. Eye color
was determined as blue, green, brown, or gray.
Upon completion of the examination, participants were requested to
deliver a blood sample for MC1R gene analyses.
Detection of MC1R gene variants Genomic DNA was isolated from
peripheral blood leukocytes by routine methods (Miller et al, 1988). A
speci®c polymerase chain reaction (PCR) product of MC1R coding
sequence (GenBank accession number X65634) was digested by either
2 U RsaI or MspI and were screened for mutations by single-stranded
conformation polymorphism analysis (Orita et al, 1989) on a 6%
polyacrylamide gel with 10% glycerol. With this technique, the gels were
run at room temperature for 6 h at 28 W or 16 h at 20 W for MspI and
RsaI digests, respectively.
PCR reaction mixtures 60 mM Tris±HCl, pH 10.0; 2.0 mM MgCl2;
15 mM (NH4)2SO4; 100 mM each deoxyguanosine triphosphate, deox-
ythymidine triphosphate, deoxyadenosine triphosphate, deoxycytidine
triphosphate; 1 ml [a-32P]deoxycytidine triphosphate (3000 Ci per
mmol), 500 ng of each PCR primer, 2 U AmpliTaq (Perkin Elmer
Cetus, PE Biosystems, Nieuwekerk, Netherlands); and 10% dimethyl
sulfoxide in a total volume of 100 ml. A 10 ml reaction was added to
50 ng genomic template DNA. Samples were covered with mineral oil,
denatured for 4 min at 92°C, and passed through 33 cycles of ampli®ca-
tion, consisting of 50 s denaturation at 92°C, 50 s primer annealing at
58°C, 2 min elongation at 72°C. The ampli®cations were carried out in
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0.5 ml tubes (Perkin Elmer). The DNA sequences of the primers were:
F-5¢CAACGACTCCTTCCTGCTTC3¢ and R-5¢TGCCCAGCACAC-
TTAAAGC3¢, resulting in a 1018 bp PCR fragment.
Sequence analysis DNA samples for sequencing were obtained by
PCR as described above with M13-tailed MC1R primers. M13MC1R-
F-5¢TGTAAAACGACGGCCAGTCAACGACTCCTTCCTGCTTC3¢
and M13MC1R-IR-5¢CAGGAAACAGCTATGACCATGAGTCACG-
ATGCTGTGG-TAGC3¢ resulted in a 542 bp fragment. The primers
M13MC1R-IF-5¢GACGTTGTAAACGACGGCCAGTACCTGCAGCT-
CCATGCTG-TC3¢ and M13MC1R-R-5¢CAGGAAACAGCTATGA-
CCATGATGCCCAGCACACTTAAAGC3¢ resulted in a 661 bp
fragment.
Sequence analysis was performed on an ABI-377 automated DNA
sequencer using Big-Dye Terminator cycle sequencing kits (Perkin
Elmer).
Statistical analysis and strategy Chi-square analysis was used to
compare MC1R gene variant frequencies in malignant melanoma patients
and controls for different skin types and hair colors. Odds ratios (OR)
with 95% con®dence intervals (CI) were calculated as an estimation of
the relative risks of cutaneous melanoma for the different MC1R gene
variants. Our analyses revealed that almost all frequently occurring
variants were associated with an increased risk of melanoma, therefore all
different MC1R gene variants were combined. Crude OR and Mantel±
Haenszel adjusted OR with a 95% con®dence were calculated to
estimate the relative risk of malignant melanoma in relation to all MC1R
genotypes combined. Skin type and hair color were considered to be
possible confounding factors in the analyses between the MC1R gene
variants and melanoma. A Mantel±Haenszel weighted odds ratio was
calculated from the results of the different skin type strata or hair color
strata to remove potential confounding caused by skin type or hair color.
RESULTS
Composition of study population The ®nal series for analysis
comprised 508 subjects: 123 patients with a history of cutaneous
melanoma and 385 control subjects. Table I shows some basic
characteristics of the study population. The majority of both
patients with cutaneous melanoma and controls were female. The
mean age of the examined melanoma patients was younger than in
the control group. Black-haired individuals were only encountered
in the control group, whereas light blond and red hair color
were overrepresented in the melanoma group. The distribution of
the different eye colors (brown, gray, green, and blue) was not
different between the melanoma patients and control group (data
not shown). Freckles and solar lentigines were more prevalent
among melanoma patients and the mean number of both common
nevi and atypical nevi was also signi®cantly higher in this group
(data not shown).
Not all MC1R variant alleles are associated with fair skin
type and red hair For the analyses of the association between
MC1R variant alleles and skin type or hair color we extended the
group of 123 patients with melanoma and 385 control subjects
with 453 patients with nonmelanoma skin cancer. The basic
characteristics of the patients with nonmelanoma skin cancer and
detailed analyses of this type of skin cancer are described elsewhere
(Bastiaens et al, 2001; De Hertog et al, 2001). Of these 961 persons,
261 (27.2%) had no MC1R variant alleles, 441 (45.9%) one MC1R
variant allele, and 259 (26.9%) two MC1R variant alleles. The
group with two variant alleles comprised of 35 homozygotes (6 3
Val60Leu who did not have red hair, 9 3 Val92Met who did not
have red hair, 1 3 Arg142His who had red hair, 5 3 Arg151Cys
who all had red hair, 13 3 Arg160Trp of whom ®ve had red hair,
and 1 3 Arg163Gln who did not have red hair) and 224
compound heterozygotes, i.e., two different variant alleles on
two separate genes. In total, 27 different MC1R±MC1R variant
alleles were found (Table IIa).
Table II(a, b) illustrate the distribution of MC1R variant alleles
among the different skin types and hair colors. Of the more
frequently occurring MC1R variant alleles the OR for the
Asp84Glu, Arg142His, Arg151Cys, Arg160Trp, His260Pro and
Asp294His variants to have fair skin and/or red hair were higher
than 2.5. The OR for the Val60Leu, Val92Met, and Arg163Gln
variant alleles, however, to have fair skin type and/or red hair were
lower than 2 (Table IIa, b).
Numerous MC1R gene variants are associated with
melanoma, which is largely independent of skin type
and hair color The distribution of MC1R variant alleles
among patients with melanoma compared with controls is
depicted in Table II(c). The majority of the most frequently
occurring MC1R variant alleles were signi®cantly associated
with a history of malignant melanoma. The distribution of
MC1R variant alleles in patients with nonmelanoma skin cancer
is also provided in Table II(c). Almost all frequently occurring
MC1R variant alleles were also signi®cantly associated with a
history of nonmelanoma skin cancer. More detailed information
about the association of MC1R variant alleles and
nonmelanoma skin cancer has been reported elsewhere
(Bastiaens et al, 2001).
Compound heterozygotes and homozygotes for the Val60Leu,
Val92Met, Arg142His, Arg151Cys, Arg160Trp, Arg163Gln, and
His260Pro variants had OR of about 4 to develop melanoma,
whereas heterozygotes for these variants had half the risk
(Table III). Adjustment for skin type did not materially alter
these OR (Table III). The presence of the MC1R gene variant
Asp84Glu appeared to impose the highest risk for cutaneous
melanoma with OR of 16.1 (95% CI 2.3±139.0) and 8.1 (95% CI
1.2±55.9) in compound heterozygotes and heterozygotes, respect-
ively, but the broad CI do not allow to draw de®nite conclusions
about the magnitude of these risks.
Almost all frequently occurring variant alleles were associated
with melanoma. Of the more frequently occurring MC1R variant
alleles, however, only the Asp84Glu, Arg142His, Arg151Cys,
Arg160Trp, His260Pro, and Asp294His variants were strongly
associated with both fair skin and red hair. The Val60Leu,
Val92Met, and Arg163Gln variant alleles, were much weaker or
not at all associated with fair skin type and/or red hair. The
different associations of MC1R gene variants with skin type and
hair color on one side and melanoma on the other side form a
strong argument that these pigmentation characteristics and
melanoma are independent outcomes of the presence of MC1R
gene variants.
To investigate further whether the association between MC1R
gene variants and melanoma is independent of skin type and hair
color, all different MC1R gene variants were combined. Table IV
shows the nonadjusted risk of cutaneous melanoma dependent on
Table I. Characteristics of the patients with melanoma and
controls
Controls
(n = 385)
Melanoma
(n = 123)
Gender N (%)
Women 222 (57.7) 76 (61.8)
Men 163 (42.3) 47 (38.2)
Age (y)
Mean 6 SD 58.5 6 11.2 49.3 6 12.1
Range 28.6±79.9 24.1±77.5
Skin type N (%)
IV: tan/never burn 24 (6.2) 3 (2.5)
III: tan/sometimes burn 181 (47.0) 34 (27.6)
II: burn/then tan 155 (40.3) 76 (61.8)
I: burn/never tan 25 (6.5) 10 (8.1)
Hair color N (%)
Black 27 (7.0) 0 (0)
Brown 97 (25.2) 31 (25.2)
Dark blond 143 (37.1) 41 (33.3)
Light blond 96 (24.9) 40 (32.5)
Red 20 (5.2) 9 (7.3)
Not recorded 2 (0.6) 2 (1.7)
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MC1R gene variants and the risks strati®ed according to and
adjusted for skin type and hair color. All MC1R gene variants
combined were also signi®cantly associated with the development
of melanoma. Carriers of two variant alleles had a relative risk for
melanoma of 4.8 (95% CI 2.5±9.4) compared with carriers of two
wild-type alleles, and carriers of one variant allele had again half the
Table II. (a) Not all MC1R variant alleles are equally strong associated with fair skin typea
Variantb
Total no.
(n = 1922)
Skin type
OR (95% CI)
Skin type I + II vs
skin type III + IV
IV
(n = 102)
N (%)
III
(n = 764)
N (%)
II
(n = 866)
N (%)
I
(n = 190)
N (%)
Wild type 963 (50.1) 65 (63.7) 459 (60.1) 383 (44.2) 56 (29.5) 1
Val60Leu (178G®T) 179 (9.3) 11 (10.8) 67 (8.8) 84 (9.7) 17 (8.9) 1.5 (1.1±2.1)
Asp84Glu (252C®A) 32 (1.7) 1 (1.0) 7 (0.9) 21 (2.4) 3 (1.6) 3.6 (1.6±8.1)
Val92Met (284G®A) 171 (8.9) 6 (5.9) 64 (8.4) 78 (9.0) 23 (12.1) 1.7 (1.2±2.4)
Arg142His (425G®A) 16 (0.8) 0 (0.0) 4 (0.5) 7 (0.8) 5 (2.6) 3.6 (2.4±5.4)
Arg151Cys (451C®T) 132 (6.9) 1 (1.0) 32 (4.2) 73 (8.4) 26 (13.7) 3.6 (2.4±5.4)
Arg160Trp (478C®T) 224 (11.7) 8 (7.8) 57 (7.5) 121 (14.0) 38 (20.0) 2.9 (2.1±4.0)
Arg163Gln (488G®A) 89 (4.6) 4 (3.9) 33 (4.3) 44 (5.1) 8 (4.2) 1.7 (1.1±2.6)
His260Pro (779 A®C) 19 (1.0) 1 (1.0) 5 (0.6) 10 (1.2) 3 (1.6) 2.6 (0.97±6.9)
Asp294His (880G®C) 20 (1.0) 0 (0.0) 6 (0.8) 9 (1.0) 5 (2.6) 2.8 (1.1±7.3)
Other variantsc 77 (4.0) 5 (4.9) 30 (3.9) 36 (4.2) 6 (3.2) 1.4 (0.90±2.3)
an = number of alleles.
bBetween brackets the nucleotide change is shown.
c< 0.5% of total alleles: Pro18Ala (52C ®G), Ala81Pro (241G ®C), Thr95Met (284C ®T), Gly104Ser (310G ®A), Arg151Arg (453C ®G), Ile155Thr (925T ®C),
Val173del, Val174Ile (981G ®A), Pro230Leu (689C ®T), Pro230Pro (690G ®A), Gln233Gln (699G ®A), Ile264Ile (792C ®T), Lys278Glu (832A ®G), Asn279Ser
(835A ®G), Asn279Lys (836C ®A), 86InsA, 537InsC, *2C ®T.
(b) Not all MC1R variant alleles are associated with red haira
Variantb
Hair color
OR (95% CI)
Red hair vs
other hair colors
Black
(n = 98)
N (%)
Brown
(n = 414)
N (%)
Dark blond
(n = 692)
N (%)
Light blond
(n = 568)
N (%)
Red
(n = 142)
N (%)
Wild type 59 (60.2) 213 (51.5) 391 (56.5) 276 (48.6) 19 (13.5) 1
Val60Leu 9 (9.2) 52 (12.6) 61 (8.8) 48 (8.5) 8 (5.6) 2.3 (1.0±5.4)
Asp84Glu 1 (1.0) 10 (2.4) 9 (1.3) 9 (1.6) 3 (2.1) 5.1 (1.4±18.3)
Val92Met 6 (6.1) 41 (9.9) 59 (8.5) 62 (10.9) 3 (2.1) 0.88 (0.26±3.0)
Arg142His 0 (0.0) 1 (0.2) 3 (0.4) 4 (0.7) 8 (5.6) 49.2 (16.8±145.5)
Arg151Cys 4 (4.1) 22 (5.3) 36 (5.2) 31 (5.5) 39 (27.5) 20.7 (11.5±37.3)
Arg160Trp 6 (6.1) 34 (8.2) 69 (10.0) 69 (12.1) 45 (31.7) 12.5 (7.1±21.9)
Arg163Gln 8 (8.2) 22 (5.3) 23 (3.3) 33 (5.8) 3 (2.1) 1.7 (0.50±5.9)
His260Pro 1 (1.0) 3 (0.7) 8 (1.2) 3 (0.5) 3 (2.1) 9.9 (2.6±37.0)
Asp294His 0 (0.0) 2 (0.5) 5 (0.7) 9 (1.6) 4 (2.8) 12.4 (3.8±40.5)
Other variantsc 4 (4.1) 14 (3.4) 28 (4.1) 24 (4.2) 7 (4.9) 4.9 (2.0±12.2)
See key see footnote for Table II(a).
(c) MC1R variant alleles are more frequently present among patients with melanoma or non-melanoma skin cancer
compared with controlsa
Variantb
Controls
(n = 770)
N (%)
Non-melanoma
skin cancer
(n = 906)
N (%)
Malignant
melanoma
(n = 246)
N (%)
OR (95% CI)
non-melanoma
skin cancer
vs controls
OR (95% CI)
malignant
melanoma
vs controls
Wild type 448 (58.2) 419 (46.2) 96 (39.0) 1 1
Val60Leu 64 (8.3) 90 (9.9) 25 (10.2) 1.5 (1.1±2.1) 1.8 (1.1±3.0)
Asp84Glu 7 (0.9) 17 (1.9) 8 (3.3) 2.6 (1.1±6.3) 5.3 (1.9±15.1)
Val92Met 53 (6.9) 93 (10.3) 25 (10.2) 1.9 (1.3±2.7) 2.2 (1.3±3.7)
Arg142His 6 (0.8) 7 (0.8) 3 (1.2) 1.2 (0.42±3.7) 2.3 (0.57±9.5)
Arg151Cys 37 (4.8) 75 (8.3) 20 (8.1) 2.1 (1.4±3.3) 2.5 (1.4±4.5)
Arg160Trp 81 (10.5) 108 (11.9) 35 (14.2) 1.4 (1.0±2.0) 2.0 (1.3±3.2)
Arg163Gln 38 (4.9) 36 (4.0) 15 (6.1) 1.0 (0.63±1.6) 1.8 (0.97±3.5)
His260Pro 3 (0.4) 10 (1.1) 6 (2.4) 3.6 (0.97±13.0) 9.3 (2.3±38.0)
Asp294His 5 (0.7) 13 (1.4) 2 (0.8) 2.8 (0.98±7.9) 1.9 (0.36±9.8)
Other variantsc 28 (3.6) 38 (4.2) 11 (4.5) 1.5 (0.87±2.4) 1.8 (0.88±3.8)
See key see footnote for Table II(a).
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risk (Table IV). After adjustment for skin type the association
between MC1R gene variants and the occurrence of melanoma
remained, suggesting that MC1R gene variants are a risk factor for
the development of melanoma independent of skin type. Similarly,
adjustment for red hair did not materially in¯uence this association
(Table IV). Unfortunately, the group of persons with red hair was
too small to attribute signi®cance to the distribution of MC1R
variant alleles within this subgroup. Signi®cant associations
between MC1R gene variants and melanoma, however, were
seen in each of the strata with brown, dark blond, and light blond
hair (data not shown).
Conversely, individuals with skin type I and II had a relative risk
for melanoma of 2.7 (95% CI 1.7±4.2) compared with skin type III
and IV. After adjustment for the presence of MC1R gene variants
the association between skin type and the risk for melanoma
remained (data not shown), indicating that also the association
between skin type and melanoma is independent of the presence of
MC1R gene variants.
Table III. Risk for cutaneous melanoma for each MC1R gene variant
Variant
(A) Heterozygotes
(B) Compound
heterozygotes
and homozygotes
Controls
(N = 385)
N (%)
Melanoma
(N = 123)
N (%)
Non-adjusted
OR (95% CI)
OR
(95% CI)
adjusted for
skin type
Wild-type
homozygotes
137 (35.6) 17 (13.8) 1 1
Val60Leu A 42 (10.9) 14 (11.4) 2.7 (1.1±6.3) 2.7 (1.1±6.3)
B 20 (5.2) 10 (8.1) 4.0 (1.5±11.0) 3.2 (1.1±8.9)
Asp84Glua A 3 (0.8) 3 (2.4) 8.1 (1.2±55.9) 10.4 (1.2±68.5)
B 2 (0.5) 4 (3.3) 16.1 (2.3±139.0) Insuf®cient data
Val92Met A 31 (8.1) 9 (7.3) 2.3 (0.87±6.2) 2.2 (0.83±6.1)
B 22 (5.7) 14 (11.4) 5.1 (2.1±12.9) 4.0 (1.4±10.1)
Arg142Hisa A 3 (0.8) 0 0 (0±19.9) Insuf®cient data
B 3 (0.8) 2 (1.6) 5.4 (0.58±44.0) 4.3 (0.41±35.6)
Arg151Cysa A 19 (4.9) 3 (2.4) 1.3 (0.27±5.3) 1.2 (0.25±5.0)
B 18 (4.7) 16 (13.0) 7.2 (2.9±18.1) 5.6 (2.2±16.2)
Arg160Trpa A 45 (11.7) 15 (12.2) 2.7 (1.2±6.2) 2.3 (0.97±5.4)
B 31 (8.1) 17 (13.8) 4.4 (1.9±10.3) 3.4 (1.4±8.5)
Arg163Gln A 18 (4.7) 6 (4.9) 2.7 (0.82±8.5) 2.6 (0.81±8.5)
B 18 (4.7) 9 (7.3) 4.0 (1.4±11.4) 3.5 (1.1±9.6)
His260Proa A 2 (0.5) 5 (4.1) 20.2 (3.1±164.7) 17.3 (2.1±126.8)
B 1 (0.3) 1 (0.8) 8.1 (0.0±312.5) 10.0 (0.19±325.7)
Asp294Hisa A 4 (1.0) 2 (1.6) 4.0 (0.47±28.8) 4.1 (0.42±28.7)
B 1 (0.3) 0 0 (0±148.2) Insuf®cient data
aVariant alleles which are strongly associated with both fair skin type and red hair color.
Table IV. Risk of melanoma dependent on MC1R gene variants strati®ed according to skin type and red hair colora
All groups together Skin type III and IV Skin type I and II
Pooled OR
Controls
N (%)
Melanoma
N (%)
Controls N (%)
N (%)
Melanoma
N (%)
Controls
N (%)
Melanoma
N (%)
Wt/wt 137 (35.6) 17 (13.8) 87 (42.4) 8 (21.6) 50 (27.8) 9 (10.5)
Wt/var 174 (45.2) 62 (50.4) 95 (46.4) 24 (64.9) 79 (43.9) 38 (44.2)
Var/var 74 (19.2) 44 (35.8) 23 (11.2) 5 (13.5) 51 (28.3) 39 (45.3)
OR1b 2.9 (1.6-5.4) 2.8 (1.1-7.1) 2.7 (1.1-6.5) 2.7 (1.5-5.1)
OR2b 4.8 (2.5-9.4) 2.4 (0.60-9.1) 4.3 (1.8-10.6) 3.6 (1.7-7.2)
All groups together Non-red hair colors Red hair color
Pooled OR
Controls
N (%)
Melanoma
N (%)
Controls N (%)
N (%)
Melanoma
N (%)
Controls
N (%)
Melanoma
N (%)
Wt/wt 136 (35.5) 16 (13.2) 136 (37.4) 16 (14.3) 0 0
Wt/var 173 (45.2) 62 (51.2) 169 (46.6) 61 (54.5) 4 (20.0) 1 (11.1)
Var/var 74 (19.3) 43 (35.6) 58 (16.0) 35 (31.2) 16 (80.0) 8 (88.9)
OR1b 3.1 (1.6-5.8) 3.1 (1.6-5.8) Insuf®cient data 3.1 (1.6-5.8)
OR2b 4.9 (2.5-9.9) 5.1 (2.5-10.6) Insuf®cient data 5.1 (2.5-10.6)
aWt represents wild type allele; Var represents variant allele.
bOR1: odds ratio comparing wt/var (heterozygotes) to wt/wt (wild type homozygotes); OR2: odds ratio comparing var/var (compound heterozygotes and homozygotes
for one variant) to wt/wt; pooled OR are adjusted for skin type or hair color using Mantel±Haenszel weighted odds ratio: OR are indicated with 95% CI in all rows.
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DISCUSSION
This study con®rmed the association of MC1R gene variants with
the occurrence of cutaneous melanoma as was reported by others
(Valverde et al, 1996; Palmer et al, 2000). Additionally, it was
shown that numerous frequently occurring MC1R gene variants
predispose to cutaneous melanoma. Despite small numbers the
Asp84Glu allele appeared to be associated with the highest risk of
cutaneous melanoma in this cohort of Dutch patients. This ®nding
is in accordance with Valverde's study who reported that the
Asp84Glu allele seemed to be of particular signi®cance in
melanoma cases (Valverde et al, 1996). The broad CI, however,
do not allow to us to draw de®nite conclusions about the
magnitude of risk of melanoma imposed by the Asp84Glu allele.
Although the strong association of MC1R gene variants with fair
skin type and red hair (Valverde et al, 1995; Flanagan et al, 2000;
Harding et al, 2000; Healy et al, 2000; Palmer et al, 2000; Box et al,
2001) could be con®rmed convincingly, our analyses also showed
that skin type and hair color did not materially in¯uence the
association between MC1R gene variants and the occurrence of
cutaneous melanoma. Separate analyses of the more commonly
occurring MC1R variant alleles showed that they were all
associated with cutaneous melanoma, although, because of the
low frequency of some variant alleles, statistical signi®cance was not
always reached. Not all MC1R variant alleles, which were
associated with melanoma, however, were also associated with
fair skin and/or red hair. Speci®cally, the Val60Leu, Val92Met, and
Arg163Gln variant alleles were weaker associated or not associated
with fair skin type and/or red hair, which further illustrates the
®nding that these pigmentation characteristics and malignant
melanoma are independent outcomes of the presence of MC1R
gene variants.
Still another argument that in cutaneous melanoma the in¯uence
of the MC1R signaling pathway may be additional to any effects on
the pigmentary phenotype comes from recent ®ndings that MC1R
gene variants are also associated with an increased risk of
nonpigmented skin cancers, such as squamous cell and basal cell
carcinoma (Table IIc; Bastiaens et al, 2001; Rees and Healy, 1997;
Box et al, 2001). All these ®ndings together strongly suggest that
MC1R gene variants in cutaneous melanoma act largely independ-
ently of the skin type or hair color phenotype, but we need further
studies to ultimately prove or disprove this hypothesis.
The exact mechanisms underlying the increased risk of individ-
uals carrying MC1R gene variants to develop melanoma are not
known. There is no doubt that fair skin and red hair impose an
important risk for the development of melanoma, but this and other
studies have shown that these pigmentary characteristics exert their
effect on melanoma risk independently of the presence of MC1R
variant alleles. On one hand, carriers of MC1R variant alleles who
have fair skin and/or red hair have a much higher melanoma risk
than carriers of the same MC1R variant alleles who have darker
skin and/or different hair colors. On the other hand, persons with a
fair skin type have a much higher risk of melanoma if they also
carry MC1R variant alleles.
An important function of the MC1 receptor obviously is
in¯uencing pigment metabolism through controlling the switch
from pheomelanin to eumelanin and hence by determining the
ability to protect against ultraviolet radiation (Healy et al, 2000). To
explain the association between MC1R gene variants and
melanoma, however, other functions of the MC1 receptor must
play an important part. Besides an in¯uence on skin melanogenesis,
a-MSH, via the MC1 receptor, also in¯uences proliferation and
differentiation of keratinocytes and melanocytes and thus may affect
growth and development of melanoma cells (Lunec et al, 1990; De
Luca et al, 1993; Abdel-Malek et al, 1995; Chakraborty et al, 1996;
Suzuki et al, 1996; Valverde et al, 1996). Furthermore, a-MSH can
exhibit immunomodulatory and anti-in¯ammatory activities via its
receptor (Wintzen and Gilchrest, 1996; Hedley et al, 1998;
Morandini et al, 1998; Luger et al, 1999; Haycock et al, 2000). It
is conceivable that the increased risk of cutaneous melanoma in
individuals carrying MC1R gene variants is modulated by the
effects of complete or partial inactivation of the MC1 receptor,
which may modulate the effects of a-MSH on proliferation and
differentiation of different cells or by hampering the immune
defense against genetically changed melanocytes.
In conclusion, the presence of MC1R gene variants appears to
play an important part in the pathogenesis of cutaneous melanoma,
although the exact mechanism underlying this increased risk
remains to be determined.
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